Send to:

Choose Destination
See comment in PubMed Commons below
J Infect Dis. 2014 Jul 1;210(1):99-110. doi: 10.1093/infdis/jiu003. Epub 2014 Jan 7.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Author information

  • 1Department of Medicine, University of Alabama at Birmingham.
  • 2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center.
  • 3Laboratory for AIDS Vaccine Research and Development, Department of Surgery, Duke University Medical Center, Durham, North Carolina.
  • 4Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center University of Washington, Seattle, Washington.
  • 5Vanderbilt University School of Medicine, Nashville, Tennessee.
  • 6University of Rochester School of Medicine and Dentistry, Rochester.
  • 7Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • 8Asociacion Civil IMPACTA Salud y Educacion, Lima, Peru.
  • 9Division of Infectious Diseases, Emory University, Atlanta.
  • 10Bridge HIV, San Francisco Department of Public Health, California.
  • 11Columbia University.
  • 12New York Blood Center, New York, New York.
  • 13Division of AIDS.
  • 14Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • 15GeoVax Inc., Smyrna, Georgia.



Clade B DNA and recombinant modified vaccinia Ankara (MVA) vaccines producing virus-like particles displaying trimeric membrane-bound envelope glycoprotein (Env) were tested in a phase 2a trial in human immunodeficiency virus (HIV)-uninfected adults for safety, immunogenicity, and 6-month durability of immune responses.


A total of 299 individuals received 2 doses of JS7 DNA vaccine and 2 doses of MVA/HIV62B at 0, 2, 4, and 6 months, respectively (the DDMM regimen); 3 doses of MVA/HIV62B at 0, 2, and 6 months (the MMM regimen); or placebo injections.


At peak response, 93.2% of the DDMM group and 98.4% of the MMM group had binding antibodies for Env. These binding antibodies were more frequent and of higher magnitude for the transmembrane subunit (gp41) than the receptor-binding subunit (gp120) of Env. For both regimens, response rates were higher for CD4(+) T cells (66.4% in the DDMM group and 43.1% in the MMM group) than for CD8(+) T cells (21.8% in the DDMM group and 14.9% in the MMM group). Responding CD4(+) and CD8(+) T cells were biased toward Gag, and >70% produced 2 or 3 of the 4 cytokines evaluated (ie, interferon γ, interleukin 2, tumor necrosis factor α, and granzyme B). Six months after vaccination, the magnitudes of antibodies and T-cell responses had decreased by <3-fold.


DDMM and MMM vaccinations with virus-like particle-expressing immunogens elicited durable antibody and T-cell responses.

© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail:


DNA; HIV/AIDS; T cells; antibodies; clinical trial; recombinant MVA; vaccines

[PubMed - indexed for MEDLINE]
[Available on 2015-07-01]

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms


Grant Support

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk